UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices) (Zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On December 27, 2022, Eton Pharmaceuticals, Inc submitted the New Drug Application response for its dehydrated alcohol injection product candidate to the U.S. Food and Drug Administration.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 28, 2022 | By: | /s/ James Gruber |
James Gruber | ||
Chief Financial Officer and Secretary | ||
(Principal Financial Officer) |
3 |
Cover |
Dec. 28, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 28, 2022 |
Entity File Number | 001-38738 |
Entity Registrant Name | ETON PHARMACEUTICALS, INC. |
Entity Central Index Key | 0001710340 |
Entity Tax Identification Number | 37-1858472 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 21925 W. Field Parkway |
Entity Address, Address Line Two | Suite 235 |
Entity Address, City or Town | Deer Park |
Entity Address, State or Province | IL |
Entity Address, Postal Zip Code | 60010-7208 |
City Area Code | (847) |
Local Phone Number | 787-7361 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | ETON |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | true |
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
&UL4$L! A0#% @ \DF<5=XT1:9? M$0 C9 L ( !.18 &9O